Abstract
Diabetes mellitus is one of the most prevalent metabolic diseases globally and it is increasing in prevalence. It is one of the most expensive diseases with respect to total health care costs per patient as a result of its chronic nature and its severe complications. To provide a more effective treatment of type 2 diabetes mellitus (T2DM), this study aims to compare different efficacies of six kinds of hypoglycemic drugs based on metformin, including glimepiride, pioglitazone, exenatide, glibenclamide, rosiglitazone, and vildagliptin, in T2DM by a network meta-analysis that were verified by randomized-controlled trials (RCTs). Eight eligible RCT in consistency with the aforementioned six hypoglycemic drugs for T2DM were included. The results of network meta-analysis demonstrated that the exenatide + metformin and vildagliptin + metformin regimens presented with better efficacy. Patients with T2DM with unsatisfactory blood glucose control based on diet control, proper exercise, and metformin treatment were included. The original regimen and dose of medication were unchanged, followed by the addition of glimepiride, pioglitazone, exenatide, glibenclamide, rosiglitazone, and vildagliptin. The results of RCTs showed that all these ...Continue Reading
References
Aug 1, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·K G Alberti, P Z Zimmet
Dec 6, 2003·International Journal of Methods in Psychiatric Research·Matthias SchützwohlUNKNOWN Eden Study Group
Dec 14, 2004·Genetic Epidemiology·Elias Zintzaras, John P A Ioannidis
Feb 10, 2006·JAMA : the Journal of the American Medical Association·Jaime L PetersLesley Rushton
May 11, 2006·Current Medical Research and Opinion·Guillermo UmpierrezAleksandra Vlajnic
Mar 20, 2008·European Heart Journal·Vincent ThijsSteffen Fieuws
Oct 14, 2008·Journal of Diabetes and Its Complications·Manuel González-OrtizTeresita J Beltrán-Jaramillo
Jan 13, 2009·Atherosclerosis·Katerina PapathanassiouLampros K Michalis
Jan 5, 2010·Wiener klinische Wochenschrift·Ligia PetricaRoxana Marian
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Shelley R SalpeterEdwin E Salpeter Posthumous
Feb 16, 2010·Diabetes Technology & Therapeutics·G DerosaA F G Cicero
Apr 30, 2011·Journal of Diabetes Science and Technology·Thomas SchöndorfAndreas Pfützner
May 19, 2011·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·G DerosaP Maffioli
Jun 8, 2011·European Journal of Pharmacology·Giuseppe DerosaPamela Maffioli
Nov 24, 2011·Diabetes & Metabolism Journal·Hyun Jeong Jeon, Tae Keun Oh
May 4, 2012·Biometrics·Han ChenJosée Dupuis
May 29, 2012·Archives of Internal Medicine·Steven G CocaChirag R Parikh
Jul 5, 2012·Clinical Cardiology·Jacob A UdellDeepak L Bhatt
Jul 6, 2012·Statistics in Medicine·Dan JacksonRichard D Riley
Feb 27, 2013·JAMA Internal Medicine·Sonal SinghJodi B Segal
Oct 8, 2013·PloS One·Anna ChaimaniGeorgia Salanti
Feb 21, 2014·Revista Brasileira de terapia intensiva·Lucas Lima FerreiraLuiz Carlos Marques Vanderlei
May 31, 2014·Metabolism: Clinical and Experimental·Giuseppe DerosaPamela Maffioli
Feb 17, 2015·Alimentary Pharmacology & Therapeutics·G-Q ZhuM-H Zheng
Mar 17, 2016·European Journal of Clinical Pharmacology·S El MessaoudiN P Riksen
Jul 5, 2016·Nutrition & Diabetes·H BrathP M Nilsson
Aug 25, 2016·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Ahmed Ak HassounJulius A Vaz
Nov 28, 2016·Clinical Therapeutics·Carrie McAdam-MarxDavid Cobden
Dec 29, 2016·Diabetes & Metabolism Journal·Kun Ho YoonJenny Han